Latest news with #EXC
Yahoo
29-05-2025
- Business
- Yahoo
Exelon (EXC) is a Top-Ranked Value Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. Chicago, IL-based Exelon Corporation completed the previously announced separation of the power generation and competitive energy business, namely Constellation Energy Corp., into a separate entity, which will trade under the symbol 'CEG'. Exelon retained the transmission and distribution utility business, which will continue to be called Exelon and trade under the symbol 'EXC'. The separation was completed on Feb 1, 2022. EXC sits at a Zacks Rank #2 (Buy), holds a Value Style Score of B, and has a VGM Score of B. Compared to the Utility - Electric Power industry's P/E of 18.1X, shares of Exelon are trading at a forward P/E of 16.1X. EXC also has a PEG Ratio of 2.5, a Price/Cash Flow ratio of 7.1X, and a Price/Sales ratio of 1.8X. Many value investors pay close attention to a company's earnings as well. For EXC, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $2.70 per share for 2025. Per share EXC boasts an average earnings surprise of 10.1%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding EXC to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelon Corporation (EXC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
21-05-2025
- Business
- Yahoo
Why Exelon (EXC) is a Great Dividend Stock Right Now
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns. Exelon (EXC) is headquartered in Chicago, and is in the Utilities sector. The stock has seen a price change of 17.59% since the start of the year. The energy company is paying out a dividend of $0.8 per share at the moment, with a dividend yield of 3.62% compared to the Utility - Electric Power industry's yield of 3.14% and the S&P 500's yield of 1.53%. In terms of dividend growth, the company's current annualized dividend of $1.60 is up 5.3% from last year. Exelon has increased its dividend 3 times on a year-over-year basis over the last 5 years for an average annual increase of 0.01%. Future dividend growth will depend on earnings growth as well as payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Exelon's current payout ratio is 58%, meaning it paid out 58% of its trailing 12-month EPS as dividend. EXC is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2025 is $2.70 per share, with earnings expected to increase 8% from the year ago period. Investors like dividends for a variety of different reasons, from tax advantages and decreasing overall portfolio risk to considerably improving stock investing profits. However, not all companies offer a quarterly payout. Big, established firms that have more secure profits are often seen as the best dividend options, but it's fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, EXC is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelon Corporation (EXC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
15-05-2025
- Business
- Yahoo
Down -9.16% in 4 Weeks, Here's Why Exelon (EXC) Looks Ripe for a Turnaround
Exelon (EXC) has been on a downward spiral lately with significant selling pressure. After declining 9.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal. So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound. However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision. The heavy selling of EXC shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 28.78. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand. This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering EXC in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 1.3% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. Moreover, EXC currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelon Corporation (EXC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Insider
03-05-2025
- Business
- Business Insider
Evercore ISI Sticks to Their Hold Rating for Exelon (EXC)
Evercore ISI analyst Durgesh Chopra maintained a Hold rating on Exelon (EXC – Research Report) yesterday and set a price target of $51.00. The company's shares closed yesterday at $46.48. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Chopra covers the Utilities sector, focusing on stocks such as Exelon, Centerpoint Energy, and CMS Energy. According to TipRanks, Chopra has an average return of 4.4% and a 56.80% success rate on recommended stocks. In addition to Evercore ISI, Exelon also received a Hold from KeyBanc's Sophie Karp in a report issued yesterday. However, on the same day, Guggenheim maintained a Buy rating on Exelon (NASDAQ: EXC). EXC market cap is currently $47.04B and has a P/E ratio of 19.00. Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXC in relation to earlier this year. Most recently, in February 2025, Honorable Colette D, the EVP, CLO & Corporate Secretary of EXC sold 1,463.00 shares for a total of $59,353.91.
Yahoo
02-05-2025
- Business
- Yahoo
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Revenue Growth: Increased by 45% compared to Q1 2024. Key Products Revenue: Grew by more than $4 billion, accounting for $7.5 billion of total revenue. Gross Margin: 83.5% in Q1, up 1 percentage point from the previous year. Marketing, Selling, and Administrative Expenses: Increased by 26%. R&D Expenses: Increased by 8%. Acquired IP R&D Charges: $1.57 billion, impacting EPS by $1.72. Non-GAAP Performance Margin: 42.6%, an increase of over 11 percentage points from Q1 2024. Effective Tax Rate: 20.2% for Q1. Earnings Per Share (EPS): $3.34, inclusive of a $1.72 negative impact from acquired IP R&D charges. US Revenue Growth: Increased by 49% in Q1. Europe Revenue Growth: Increased by 71% in constant currency. Japan Revenue Growth: Increased by 15% in constant currency. China Revenue Growth: Increased by 21% in constant currency. Rest of World Revenue Growth: Increased by 17% in constant currency. Mounjaro Sales: $3.8 billion, more than double from the previous year. Zepbound Sales: Increased by $1.8 billion to $2.3 billion in the quarter. Dividends and Share Repurchase: $1.3 billion in dividends and $1.2 billion in share repurchase. Warning! GuruFocus has detected 12 Warning Signs with EXC. Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Eli Lilly and Co (NYSE:LLY) reported a 45% increase in revenue compared to Q1 2024, driven by key products such as Mounjaro and Zepbound. The company achieved several key pipeline milestones, including the approval of Jaypirca in the EU for CLL and Omvoh in the US, EU, and Japan for Crohn's disease. Eli Lilly and Co (NYSE:LLY) shared promising Phase III clinical data for orforglipron, an oral GLP-1, showing potential for significant impact in Type 2 diabetes and obesity. The company announced plans to more than double its US manufacturing investment, with over $50 billion in new investments since 2020. Eli Lilly and Co (NYSE:LLY) distributed $1.3 billion in dividends and executed a $1.2 billion share repurchase in Q1 2025. Marketing, selling, and administrative expenses increased by 26%, driven by promotional activities for new launches. R&D expenses rose by 8%, primarily due to higher development costs for late-stage assets and early-stage research investments. The company recognized acquired IP R&D charges of $1.57 billion, negatively impacting earnings per share by $1.72. Eli Lilly and Co (NYSE:LLY) faces potential challenges from tariffs and trade dynamics, which could negatively affect its financial outlook if expanded. The company withdrew its US application for the heart failure with preserved ejection fraction indication for tirzepatide, as the FDA requires an additional confirmatory clinical trial. Q: In light of the CVS formulary announcement, what is your expectation on market share dynamics for Mounjaro and Zepbound, and how will you navigate the PBM environment? A: David Ricks, CEO, stated that while the CVS announcement was not surprising, Lilly is focused on expanding choice and access rather than reducing it. The company aims to continue driving share and preference for its brands, emphasizing the development of innovative medicines like orforglipron, which offers the convenience of an oral GLP-1 with injectable-like efficacy. Q: What is the strategic positioning of orforglipron in the market, and are there plans for broader indications beyond diabetes and obesity? A: Daniel Skovronsky, Chief Scientific Officer, highlighted that orforglipron's oral convenience makes it suitable for broad primary care indications. Lilly plans to pursue various directions, including potential combinations with other mechanisms in immunology and neuroscience. The company is also developing additional oral incretins and multifunctional orals. Q: How do you see orforglipron competing in the core obesity and diabetes market relative to injectables, and what share do you envision for orals? A: Patrik Jonsson, President of Lilly Cardiometabolic Health, noted that orforglipron has significant opportunities, particularly as 50% of Type 2 diabetes patients prefer oral medication. The oral form allows for greater scalability and global reach compared to injectables, positioning it as a first-line incretin for both Type 2 diabetes and chronic weight management. Q: Can you discuss the pricing strategy for orforglipron and how having a portfolio of weight loss medications might impact PBM discussions? A: Patrik Jonsson explained that while specific pricing details are not disclosed until launch, having a portfolio allows Lilly to target different patient segments effectively. David Ricks added that Lilly aims to reduce the gap between list and net prices, promoting more transparent pricing and reducing rebate flows. Q: Regarding the CVS announcement, how do you view this development in terms of GLP-1 market dynamics and access? A: David Ricks expressed that while the CVS decision might reduce choice, Lilly's focus remains on innovation and differentiation. The company believes in expanding access and choice, and despite the CVS decision, Lilly will continue to drive innovation and market growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
